Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 700 Saginaw Dr REDWOOD CITY CA 94063-4752 |
Tel: | 1-415-6757401 |
Website: | https://www.revmed.com |
IR: | See website |
Key People | ||
Mark A. Goldsmith Chairman of the Board, President, Chief Executive Officer | Jack Lee Anders Chief Financial Officer | Steve Kelsey President - Research and Development |
Margaret A. Horn Chief Operating Officer | Xiaolin Wang Executive Vice President - Clinical Development | Jeff Cislini Senior Vice President, General Counsel, Company Secretary |
Alicia Gardner Senior Vice President - Commercial | Lin Wei Chief Medical Officer |
Business Overview |
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company's research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company's RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers. |
Financial Overview |
For the three months ended 31 March 2024, Revolution Medicines Inc revenues decreased from $7M to $0K. Net loss increased 70% to $116M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 70% to $107.8M (expense), General and administrative - Balancing increase of 83% to $16.9M (expense). |
Employees: | 411 as of Mar 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4,442M as of Mar 31, 2024 |
Annual revenue (TTM): | $4.57M as of Mar 31, 2024 |
EBITDA (TTM): | -$546.34M as of Mar 31, 2024 |
Net annual income (TTM): | -$484.27M as of Mar 31, 2024 |
Free cash flow (TTM): | -$457.88M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 164,986,227 as of May 2, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |